Bionano Genomics (BNGO) Accumulated Expenses (2017 - 2026)

Bionano Genomics (BNGO) has 10 years of Accumulated Expenses data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 1.5% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 1.5% YoY), and the FY2025 full-year result was $3.5 million, down 37.3% from the prior year.
• Accumulated Expenses advanced to $4.0 million in Q1 2026, from $3.5 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $11.7 million in Q3 2022 to a low of $3.4 million in Q2 2025.
• A 5-year average of $7.3 million and a median of $7.8 million in 2022 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 91.8% in 2022 and tumbled 64.3% in 2025, its largest moves.
• Tracing BNGO's Accumulated Expenses over 5 years: stood at $10.6 million in 2022, then decreased by 23.34% to $8.1 million in 2023, then plunged by 30.26% to $5.6 million in 2024, then sank by 37.3% to $3.5 million in 2025, then grew by 12.98% to $4.0 million in 2026.
• Business Quant data shows BNGO's Accumulated Expenses at $4.0 million in Q1 2026, $3.5 million in Q4 2025, and $4.7 million in Q3 2025.